View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsTRACON Pharmaceuticals 過去の業績過去 基準チェック /26TRACON Pharmaceuticalsは14.5%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで30%毎年増加している。売上は成長しており、年平均82.6%の割合である。主要情報14.49%収益成長率58.99%EPS成長率Biotechs 業界の成長17.04%収益成長率82.56%株主資本利益率n/aネット・マージン162.34%前回の決算情報30 Jun 2024最近の業績更新TRACON Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024May 09TRACON Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024Feb 29TRACON Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023Nov 01TRACON Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023Aug 03TRACON Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 10, 2023May 04TRACON Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022Nov 01すべての更新を表示Recent updatesTRACON Pharmaceuticals, Inc. Common Stock to Be Deleted from OTC EquityDec 04TRACON Pharmaceuticals Files Form 15Nov 08TRACON Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10 million.Nov 01TRACON Pharmaceuticals Announces It Will Wind Down OperationsJul 31+ 1 more updateTRACON Pharmaceuticals Notifies Nasdaq of its Withdrawal of the AppealJul 17TRACON Pharmaceuticals Announces Termination of Envasarc Trial and Will Explore Strategic Alternatives Leveraging Its In-House Product Development PlatformJul 01TRACON Pharmaceuticals, Inc.(OTCPK:TCON) dropped from NASDAQ Composite IndexJun 28Investor sentiment improves as stock rises 16% Jun 27The Nasdaq Hearings Panel Determines to Delist TRACON Pharmaceuticals' Common Stock from Nasdaq Due to Non-Compliance with Continued Listing Requirements by June 3, 2024Jun 15Price target decreased by 19% to US$30.50 May 16Forecast to breakeven in 2026 May 15TRACON Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024May 09TRACON Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.Apr 14TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as PlannedApr 03Insufficient new directors Apr 01New major risk - Share price stability Mar 13New major risk - Shareholder dilution Mar 06TRACON Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024Feb 29TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 TrialDec 20Consensus EPS estimates upgraded to US$0.45 loss Nov 16TRACON Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023Nov 01New major risk - Revenue and earnings growth Oct 29New major risk - Share price stability Oct 11TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as PlannedSep 19New major risk - Financial position Aug 19Consensus revenue estimates increase by 50% Aug 17TRACON Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023Aug 03TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal TrialJun 21TRACON Pharmaceuticals Receives Notice from Nasdaq Regarding Non-Compliance with the Market Value Rule and Minimum Bid Price RequirementJun 12Consensus revenue estimates increase by 100% May 17Price target decreased by 21% to US$7.33 May 14TRACON Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 10, 2023May 04Price target decreased by 12% to US$9.33 Apr 17No longer forecast to breakeven Mar 10TRACON Pharmaceuticals Receives A Letter from Nasdaq Regarding Market Value RuleJan 02TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal TrialDec 16TRACON Pharmaceuticals, Inc Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line SarcomaNov 22Price target decreased to US$10.20 Nov 16TRACON Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022Nov 01TRACON Pharmaceuticals, Inc. Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from Envasarc Phase 2 Pivotal TrialOct 07TRACON Pharmaceuticals Announces Fast Track Designation by the Food and Drug Administration for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFSSep 15Tracon Pharmaceuticals announces $35M non-dilutive debt facility Sep 06Biocytogen Pharmaceuticals (Beijing) Co., Ltd. and TRACON Pharmaceuticals, Inc. Announce U.S. Food and Drug Administration Approval of Investigational New DrugAug 30+ 1 more updateTracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma Aug 29Consensus forecasts updated Aug 17TRACON Pharmaceuticals, Inc. Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal TrialAug 11Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M Aug 10TRACON Pharmaceuticals, Inc. Submits IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-Line Sarcoma Patients in Combination with EnvafolimabAug 09TRACON Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 10, 2022Jul 28TRACON Pharmaceuticals Announces Dosing of 36Th Patient in Envasarc Pivotal Trial Triggering Initial Idmc Efficacy Review Expected in the Fourth QuarterJul 27Consensus revenue estimates increase by 99% May 18TRACON Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 11, 2022May 05TRACON Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022Apr 26Forecast to breakeven in 2024 Apr 21TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.KApr 20No longer forecast to breakeven Mar 18No longer forecast to breakeven Mar 16TRACON Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 15, 2022Mar 06TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer InstituteFeb 03TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal TrialDec 28TRACON Pharmaceuticals, Inc. Reports Regulatory Approval of Envafolimab in ChinaDec 01TRACON Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.Jul 24TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual MeetingJun 05TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal TrialJun 02TRACON Pharmaceuticals, Inc. Announces Appointment of Lisa Johnson-Pratt to its Board of DirectorsMar 10TRACON Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $8.805977 million.Feb 26+ 1 more updateTRACON Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021Feb 19Tracon Pharmaceuticals, Inc. Announces Executive ChangesFeb 03+ 1 more updateTRACON Pharmaceuticals, Inc. Announces Dosing of First Patient in ENVASARC Pivotal TrialDec 11TRACON Pharmaceuticals, Inc. Announces Publication in Cancer Cell of Clinical Data That Provides Molecular Insight into the Mechanism of Action of Trc102 and Patient Populations Most Likely to Respond to TreatmentNov 25TRACON Pharmaceuticals Announces Submission for Approval of Envafolimab (KN035) with the NMPA in China by its Corporate Partners Alphamab Oncology and 3D MedicinesNov 18TRACON Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 10, 2020Nov 05Tracon Pharmaceuticals Highlights Updated Envafolimab Clinical Results in MSI-H/dMMR Colorectal CancerSep 22TRACON Pharmaceuticals, Inc. announced that it expects to receive $4.999998 million in funding from Opaleye Management Inc.Aug 28収支内訳TRACON Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:TCON 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費30 Jun 24355-531 Mar 241226031 Dec 2312-47030 Sep 239-117830 Jun 239-288831 Mar 230-2810031 Dec 220-2914030 Sep 220-3017030 Jun 220-3019031 Mar 220-3321031 Dec 210-2918030 Sep 210-2515030 Jun 210-2213031 Mar 210-189031 Dec 200-178030 Sep 200-168030 Jun 200-188-331 Mar 200-198031 Dec 190-238030 Sep 190-268-530 Jun 190-308031 Mar 190-347-231 Dec 183-357030 Sep 183-347730 Jun 1810-247631 Mar 1811-207631 Dec 179-198030 Sep 179-198730 Jun 173-268731 Mar 173-288731 Dec 163-278630 Sep 164-328630 Jun 165-327631 Mar 168-277631 Dec 158-246530 Sep 158-165430 Jun 158-124431 Mar 154-103331 Dec 144-72330 Sep 143-72230 Jun 141-72231 Mar 140-822質の高い収益: TCONには$15.0M } という大きな 一回限りの 利益があり、過去 12 か月の財務実績が30th June, 2024に影響を及ぼしています。利益率の向上: TCON過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: TCON過去 5 年間で収益を上げており、収益は年間14.5%増加しています。成長の加速: TCONは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: TCON昨年収益を上げたため、昨年の収益成長をBiotechs業界 ( 40.2% ) と比較することは困難です。株主資本利益率高いROE: TCONの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/12/04 04:40終値2024/12/02 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋TRACON Pharmaceuticals, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12 アナリスト機関Matthew CrossAlliance Global PartnersJoel BeattyBairdnull nullBTIG9 その他のアナリストを表示
TRACON Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10 million.Nov 01
TRACON Pharmaceuticals Announces Termination of Envasarc Trial and Will Explore Strategic Alternatives Leveraging Its In-House Product Development PlatformJul 01
The Nasdaq Hearings Panel Determines to Delist TRACON Pharmaceuticals' Common Stock from Nasdaq Due to Non-Compliance with Continued Listing Requirements by June 3, 2024Jun 15
TRACON Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.Apr 14
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as PlannedApr 03
TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 TrialDec 20
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as PlannedSep 19
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal TrialJun 21
TRACON Pharmaceuticals Receives Notice from Nasdaq Regarding Non-Compliance with the Market Value Rule and Minimum Bid Price RequirementJun 12
TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal TrialDec 16
TRACON Pharmaceuticals, Inc Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line SarcomaNov 22
TRACON Pharmaceuticals, Inc. Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from Envasarc Phase 2 Pivotal TrialOct 07
TRACON Pharmaceuticals Announces Fast Track Designation by the Food and Drug Administration for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFSSep 15
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. and TRACON Pharmaceuticals, Inc. Announce U.S. Food and Drug Administration Approval of Investigational New DrugAug 30+ 1 more update
TRACON Pharmaceuticals, Inc. Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal TrialAug 11
TRACON Pharmaceuticals, Inc. Submits IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-Line Sarcoma Patients in Combination with EnvafolimabAug 09
TRACON Pharmaceuticals Announces Dosing of 36Th Patient in Envasarc Pivotal Trial Triggering Initial Idmc Efficacy Review Expected in the Fourth QuarterJul 27
TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.KApr 20
TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer InstituteFeb 03
TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal TrialDec 28
TRACON Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.Jul 24
TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual MeetingJun 05
TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal TrialJun 02
TRACON Pharmaceuticals, Inc. Announces Appointment of Lisa Johnson-Pratt to its Board of DirectorsMar 10
TRACON Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $8.805977 million.Feb 26+ 1 more update
TRACON Pharmaceuticals, Inc. Announces Publication in Cancer Cell of Clinical Data That Provides Molecular Insight into the Mechanism of Action of Trc102 and Patient Populations Most Likely to Respond to TreatmentNov 25
TRACON Pharmaceuticals Announces Submission for Approval of Envafolimab (KN035) with the NMPA in China by its Corporate Partners Alphamab Oncology and 3D MedicinesNov 18
Tracon Pharmaceuticals Highlights Updated Envafolimab Clinical Results in MSI-H/dMMR Colorectal CancerSep 22
TRACON Pharmaceuticals, Inc. announced that it expects to receive $4.999998 million in funding from Opaleye Management Inc.Aug 28